ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast
- PMID: 30392600
- DOI: 10.1016/j.jacr.2018.09.017
ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast
Abstract
Although the majority of male breast problems are benign with gynecomastia as the most common etiology, men with breast symptoms and their referring providers are typically concerned about whether or not it is due to breast cancer. If the differentiation between benign disease and breast cancer cannot be made on the basis of clinical findings, or if the clinical presentation is suspicious, imaging is indicated. The panel recommends the following approach to breast imaging in symptomatic men. In men with clinical findings consistent with gynecomastia or pseudogynecomastia, no imaging is routinely recommended. If an indeterminate breast mass is identified, the initial recommended imaging study is ultrasound in men younger than age 25, and mammography or digital breast tomosynthesis in men age 25 and older. If physical examination is suspicious for a male breast cancer, mammography or digital breast tomosynthesis is recommended irrespective of patient age. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Keywords: AUC; Appropriate Use Criteria; Appropriateness Criteria; Digital breast tomosynthesis; Gynecomastia; Male breast cancer; Mammography; Pseudogynecomastia; Ultrasound.
Copyright © 2018 American College of Radiology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
ACR Appropriateness Criteria® Evaluation of Nipple Discharge.J Am Coll Radiol. 2017 May;14(5S):S138-S153. doi: 10.1016/j.jacr.2017.01.030. J Am Coll Radiol. 2017. PMID: 28473070 Review.
-
ACR Appropriateness Criteria® Breast Implant Evaluation.J Am Coll Radiol. 2018 May;15(5S):S13-S25. doi: 10.1016/j.jacr.2018.03.009. J Am Coll Radiol. 2018. PMID: 29724416
-
ACR Appropriateness Criteria® Breast Pain.J Am Coll Radiol. 2018 Nov;15(11S):S276-S282. doi: 10.1016/j.jacr.2018.09.014. J Am Coll Radiol. 2018. PMID: 30392596
-
ACR Appropriateness Criteria® Palpable Breast Masses.J Am Coll Radiol. 2017 May;14(5S):S203-S224. doi: 10.1016/j.jacr.2017.02.033. J Am Coll Radiol. 2017. PMID: 28473077 Review.
-
ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update.J Am Coll Radiol. 2023 May;20(5S):S146-S163. doi: 10.1016/j.jacr.2023.02.013. J Am Coll Radiol. 2023. PMID: 37236740 Review.
Cited by
-
Detection of benign granular cell tumor of the breast via 18F-PSMA-PET/CT in a patient with very high-risk prostate cancer: A case report.SAGE Open Med Case Rep. 2024 Aug 31;12:2050313X241275826. doi: 10.1177/2050313X241275826. eCollection 2024. SAGE Open Med Case Rep. 2024. PMID: 39224763 Free PMC article.
-
Clinicopathological analysis of 38 male patients diagnosed with breast cancer.Breast Dis. 2024;43(1):1-8. doi: 10.3233/BD-230050. Breast Dis. 2024. PMID: 38363600 Free PMC article.
-
Commentary and Updates on the Management of Male Breast Cancer.Ann Surg Oncol. 2025 Apr;32(4):2265-2270. doi: 10.1245/s10434-024-16756-x. Epub 2025 Jan 13. Ann Surg Oncol. 2025. PMID: 39806047 Free PMC article. No abstract available.
-
Male Breast Cancer Review. A Rare Case of Pure DCIS: Imaging Protocol, Radiomics and Management.Diagnostics (Basel). 2021 Nov 25;11(12):2199. doi: 10.3390/diagnostics11122199. Diagnostics (Basel). 2021. PMID: 34943439 Free PMC article.
-
Male Breast Cancer: Current Scenario and Future Perspectives.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241261836. doi: 10.1177/15330338241261836. Technol Cancer Res Treat. 2024. PMID: 39043043 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical